[go: up one dir, main page]

DK1078006T3 - Diagnose og behandling af leverlidelser - Google Patents

Diagnose og behandling af leverlidelser

Info

Publication number
DK1078006T3
DK1078006T3 DK99922996T DK99922996T DK1078006T3 DK 1078006 T3 DK1078006 T3 DK 1078006T3 DK 99922996 T DK99922996 T DK 99922996T DK 99922996 T DK99922996 T DK 99922996T DK 1078006 T3 DK1078006 T3 DK 1078006T3
Authority
DK
Denmark
Prior art keywords
disorders
madcam
disorder
compositions
useful
Prior art date
Application number
DK99922996T
Other languages
English (en)
Inventor
Sherman Fong
Kenneth J Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1078006T3 publication Critical patent/DK1078006T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99922996T 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser DK1078006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7840598A 1998-05-13 1998-05-13
PCT/US1999/010520 WO1999058573A1 (en) 1998-05-13 1999-05-12 Diagnosis and treatment of hepatic disorders

Publications (1)

Publication Number Publication Date
DK1078006T3 true DK1078006T3 (da) 2009-06-02

Family

ID=22143829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99922996T DK1078006T3 (da) 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser

Country Status (10)

Country Link
EP (1) EP1078006B1 (da)
JP (2) JP4817494B2 (da)
AT (1) ATE424417T1 (da)
AU (1) AU3986699A (da)
CA (1) CA2330000C (da)
DE (1) DE69940503D1 (da)
DK (1) DK1078006T3 (da)
ES (1) ES2321994T3 (da)
IL (2) IL139129A0 (da)
WO (1) WO1999058573A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257388T3 (es) * 2001-11-05 2006-08-01 Warner-Lambert Company Llc Procedimientos y composiciones para la seleccion de integrinas.
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
CN1956738B (zh) * 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
ATE483732T1 (de) * 2005-07-08 2010-10-15 Pfizer Ltd Madcam-antikörper
JP5847188B2 (ja) * 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. sVCAMおよび/またはsMAdCAMレベルの差を関連付けることにより、アルファ−4インテグリン活性の差を決定するための方法
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP6970975B2 (ja) * 2016-07-20 2021-11-24 国立大学法人京都大学 IgG4関連疾患の検査方法
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
US20200392231A1 (en) * 2017-12-06 2020-12-17 Emory University Methods of Managing Hepatic Steatosis
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT808367E (pt) * 1995-02-10 2007-10-22 Millennium Pharm Inc Adressinas vasculares da mucosa e suas utilizações
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Also Published As

Publication number Publication date
EP1078006A1 (en) 2001-02-28
CA2330000A1 (en) 1999-11-18
AU3986699A (en) 1999-11-29
JP4817494B2 (ja) 2011-11-16
IL139129A (en) 2006-09-05
JP2002514660A (ja) 2002-05-21
IL139129A0 (en) 2001-11-25
WO1999058573A1 (en) 1999-11-18
ES2321994T3 (es) 2009-06-15
JP2010280659A (ja) 2010-12-16
ATE424417T1 (de) 2009-03-15
EP1078006B1 (en) 2009-03-04
DE69940503D1 (de) 2009-04-16
CA2330000C (en) 2015-06-23

Similar Documents

Publication Publication Date Title
Heneka et al. Neuroinflammation in Alzheimer's disease
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
DK1078006T3 (da) Diagnose og behandling af leverlidelser
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EP2801366A3 (en) Improved apo E analogs and methods for their use
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DE60035870D1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
Sewal et al. Increase in seizure susceptibility in sepsis like condition explained by spiking cytokines and altered adhesion molecules level with impaired blood brain barrier integrity in experimental model of rats treated with lipopolysaccharides
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
EA200101212A1 (ru) Замещенные полициклические арил- и гетероарилпиразиноны, которые могут использоваться при селективном ингибировании системы свертывания крови
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
WO2005023189A3 (en) Method of cox-2 selective inhibitor and nitric oxide-donating agent
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
BRPI0416591A (pt) métodos e reagentes para o tratamento de distúrbios inflamatórios
FI955261A0 (fi) P-selektiinin vasta-aineita ja niiden käyttö